3Vote!
You can call me Rick (Free subscription) | yesterday
Here's a budget balancing idea that's keyed to health care, The Botax. There are already taxes on death, luxury and sin, how about a tax on vanity? Under the Senate's proposal, there could be a five percent tax on cosmetic procedures and surgeries. There were nearly 5 million last year and an average cost per visit of about $400, some including several injections. That's $2 billion spent on just one...
+Vote!
Jolie Nadine (Free subscription) | yesterday
Leaping lizards, I followed through on my promise to write more about Latisse! (Baby victories here, people.) As I mentioned last month, I’ve started using Latisse, which is a new treatment from Allergan designed to make your eyelashes grow like weeds. Frankly, I was terrified to start using it, because I’d heard a lot of [...]
3Vote!
Market Watch (Free subscription) | 19/11/2009
BOSTON (MarketWatch) -- Allergan Inc. and Medicis Pharmaceutical Corp. led drug stocks lower early Thursday as shares of the dermatology-products makers fell on news that a new bill unveiled by Senate Democrats would levy a 5% excise tax on cosmetic procedures. The NYSE Arca Pharmaceutical Index and the NYSE Arca Biotechnology Index were both down 1.4% at 298.94 and 872.60, respectively. Shares of...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 10/11/2009
Allergan (NYSE: AGN) hit a new 52-Week high of $60.25 so far today. Currently the stock is up $0.10 (0.16%) to $59.97 on 712,947 shares traded. Today's high is up $31.02 from a 52-Week Low of $28.95. Allergan stock has been showing support around $56.76 and resistance in the $61.46 range. Technical indicators for the stock are neutral and S&P gives AGN a n...
3Vote!
GuruFocus Updates (Free subscription) | 09/11/2009
By insider. EVP, Fin & Bus. Dev., CFO of Allergan Inc. ( AGN ) Jeffrey L Edwards sells 32,592 shares of AGN on 11/06/2009 at an average price of $59.27 a share. Read more » »
4Vote!
Kim Stagliano (Free subscription) | 09/11/2009
Brooke Shields Promotes Rx to Grow Eyelashes. I saw an ad last night for this new prescription product (which to me, makes it a drug) called " Latisse ." In 4 months you can have longer lashes. Jumping Jiminy on a stick, what crap will women fall for next and is there nothing some doctors won't sell to their patients? Brooke Shields is the spokesformermodel hardly needs more hair on her eye...
5Vote!
Medical News Today (Free subscription) | 09/11/2009
St. Louis-based The Lowe Law Firm has filed a lawsuit on behalf of a man who experienced partial respiratory paralysis and other side effects after receiving an overdose of the Botox being used to treat his muscle spasticity. The suit, Richard A. Hart v. Yi Pan, Tenet HealthSystem SL Inc., d/b/a St. Louis University Hospital and Allergan USA Inc., cause no. 0922-CC09485, was filed in St.
3Vote!
Business Wire (Free subscription) | 06/11/2009
ST. LOUIS--(BUSINESS WIRE)--St. Louis-based The Lowe Law Firm has filed a lawsuit on behalf of a man who experienced partial respiratory paralysis and other side effects after receiving an overdose of the Botox being used to treat his muscle spasticity. The suit, Richard A. Hart v. Yi Pan, Tenet HealthSystem SL Inc., d/b/a St. Louis University Hospital and Allergan USA Inc., cause no. 0922-CC09485,...
3Vote!
PR News Wire (Free subscription) | 06/11/2009
DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® ophthalmic solution on the first day following patent expiration. This strength of ketorolac...
3Vote!
PR News Wire (Free subscription) | 06/11/2009
DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® opthalmic solution on the first day following patent expiration. This strength of ketorolac...
3Vote!
Toronto Cosmetic Clinic Blog (Free subscription) | 04/11/2009
A visitor to our blog made a comment recently, and we thought it would be interesting to share with the rest of you who want to know about the eyelash lengthener, Latisse. Hi, Is there any update as to when Latisse will be available in Canada? I’ve tried ordering it online, only to get it rejected during [...] A Comment About Latisse is a post from: Toronto Cosmetic Clinic Blog Related posts:...
4Vote!
Terra Sigillata (Free subscription) | 04/11/2009
I am running out of eyelash puns having written at least six posts since the summer of 2007 on a class of anti-glaucoma drugs that have been harnessed for their cosmetic side effect: promotion of eyelash growth. Bimatoprost (Lumigan®) and latanoprost (Xalatan®) are members of the prostamide class of drugs that can manage some forms of glaucoma by reducing intraocular pressure. When administered...
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS.
Two days later I was BLIND
Use Google and enter EPOCRATES...
anonymous - 12/11/2009
3Vote!
Biotech Blog (Free subscription) | 02/11/2009
Copyright © BiotechBlog.com, a product of thinkBiotech.com Drug Patent Expirations for November 2009 Tradename Applicant Generic Name Patent Number Patent Expiration ACULAR LS Allergan ketorolac tromethamine 5,110,493*PED Nov 5, 2009 ACULAR Allergan ketorolac tromethamine 5,110,493*PED Nov 5, 2009 PREVPAC Takeda Pharms Na amoxicillin; clarithromycin; lansoprazole 4,628,098*PED Nov 10, 2009 PREVACID...
3Vote!
BloggingStocks (Free subscription) | 31/10/2009
Filed under: Earnings reports , Allergan (AGN) , Aetna Inc (AET) , TD AmeriTrade Holding (AMTD) , RadioShack Corp (RSH) , Goodyear Tire and Rubber (GT) , E*TRADE (ETFC) , Visa Inc. (V) Here are some highlights from last week's earnings coverage from BloggingStocks: Aetna Inc. (NYSE: AET ) reported better-than-expected Q3 earnings and revenue, sending shares higher. Allergan Inc. (NYSE: AGN ) reported...
Explore : Aetna,
Drug Manufacturers,
Estée Lauder,
Financial Services,
Goodyear,
Health Care Services,
Health Industries,
Hygiene and Cosmetics,
Investment Brokerage,
Money,
NASDAQ,
New York Stock Exchange,
RadioShack,
SAP,
Software,
Software and services,
Stock exchange,
TD AmeriTrade Holding,
Tires
Videos